^
    8d
    TQB3720-I-01: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets (clinicaltrials.gov)
    P1, N=192, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=120 --> 192 | Trial completion date: May 2023 --> Dec 2025 | Recruiting --> Terminated; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    TQB3720
    3years
    Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis. (PubMed, Front Pharmacol)
    PCa cells and nude mice models were divided into TQB3720, enzalutamide (ENZ), and control groups. TQB3720 promotes ferroptosis in prostate cancer cells by reducing the AR/SP1 transcriptional complex binding to GPX4 promoter. As a result, it is suggested to be a potential drug for clinic prostate cancer treatment.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • GPX4 (Glutathione Peroxidase 4)
    |
    AR expression
    |
    Xtandi (enzalutamide) • TQB3720